Australia markets closed

SGEN Jan 2025 90.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
119.500.00 (0.00%)
At close: 10:54AM EST
Full screen
Previous close119.50
OpenN/A
Bid123.00
Ask128.00
Strike90.00
Expiry date2025-01-17
Day's range119.50 - 119.50
Contract rangeN/A
VolumeN/A
Open interest2
  • Yahoo Finance Video

    M&A market: What will it look like in 2024?

    The top three U.S. M&A deals of 2023 by deal value include, Exxon (XOM) acquiring Pioneer (PXD), Chevron's (CVX) acquisition of Hess (HES), and Pfizer (PFE) acquiring Seagen (SGEN), according to Dealogic. The KPMG 2024 M&A Outlook Survey found that 7 in 10 dealmakers are working currently on deals and 2 out of 3 said 2024 will be more active. KPMG Head of Deal Advisory & Strategy Carole Streicher joins Yahoo Finance Live to discuss the survey's findings and what 2024 will look like for mergers and acquisitions. "If you unpack what we think '24 is going to look like, based on the survey respondents, it's quite interesting compared to our private equity versus corporate," Streicher notes. "If you look at the first half of the year, our corporates are saying that they're going to be more active in doing deals. And in the second half of the year, our private equity clients and survey respondents are saying they're more likely to be active in doing a deal." "Our corporates are much more concerned about transformation of their business... whereas private equity is more cautious around interest rates," Streicher adds. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • PR Newswire

    PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

    Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-con

  • Yahoo Finance

    Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House

    The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.